Close Menu

NEW YORK (GenomeWeb) – Epigenomics today reported a 55 percent drop in its 2017 revenues, a decline the company attributed in part to fewer orders for its Epi proColon colorectal cancer test.

For the year ended Dec. 31, Epigenomics posted revenues of €1.9 million ($2.3 million) from €4.2 million the year before. Revenues of about 1.3 million were generated through licensing income, while product sales for the year were approximately 500,000, the firm said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.